Jeito Capital has closed a new €1 billion fund, marking the largest-ever private equity fund dedicated to biotech in Europe. The Paris-based firm, founded in 2020 by Rafaèle Tordjman and previously known for its €534 million first fund, will use the capital to support 12-15 late-stage biotech companies with global ambitions.
The fund, named Jeito II, attracted strong backing from a diverse group of international institutional investors, including pension funds, sovereign wealth funds, and insurers from Europe, North America, and Asia. This substantial commitment underscores growing investor confidence in the European life sciences sector.
Jeito Capital’s strategy focuses on providing significant, long-term capital to companies developing transformative therapies, particularly in areas like oncology, rare diseases, and immunology. The firm emphasizes active partnership, often taking board seats and supporting portfolio companies through clinical development, regulatory processes, and commercial expansion.
This record fundraising signals a maturation of the European biotech investment landscape, enabling firms to finance large-scale, late-stage trials without forcing premature exits. It positions Jeito as a major force in bridging the gap between scientific innovation and global market delivery for European biotechs.